Switch Language
Alt tag

Never miss out on the latest news!

Sign up to the Thrombosis Adviser newsletter.



See Also

Peripheral Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences


This section describes the mechanistic basis of the coagulation cascade and the roles of its various components

Coagulation Cascade Explained

Video to explain the mode of action of coagulation cascade. Play this video to get an overview about the coagulation cascade.

Video title

YYMMDD Author/Uploaded by

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

© 2017, Bayer AG. All rights reserved. Approval number: PP-XAR-ALL-0090-1

  • The coagulation process that leads to haemostasis involves a complex set of reactions involving approximately 30 different proteins1
    • These reactions convert fibrinogen, a soluble protein, to insoluble strands of fibrin, which, together with platelets, forms a stable thrombus
  • Several coagulation cascade models have been proposed


  • The intrinsic and extrinsic pathway model divides the initiation of coagulation into two distinct parts1
    • The extrinsic pathway is thought to be responsible for the initial generation of activated Factor X (Factor Xa)
    • The intrinsic pathway leads to amplification of Factor Xa generation
  • Factor Xa plays a central role in the coagulation cascade because it occupies a point at which the intrinsic and extrinsic pathways converge


  • The cell-based model includes the important interactions between cells directly involved in haemostasis (i.e. TF-bearing cells and platelets) and coagulation factors
    • It more accurately represents the interaction between cellular activity and coagulation proteins that leads to thrombus formation and haemostasis2
  • The cell-based model identifies the membranes of TF-bearing cells and platelets as the sites where activation of specific coagulation factors occurs in a three-phase process:2
    • Initiation
    • Amplification
    • Fibrin formation


  • Initiation occurs after vascular injury, when TF-bearing cells bind to and activate Factor VII
  • This leads to the production of a small amount of thrombin


  • A small amount of thrombin activates platelets
  • Prothrombinase complex (comprising Factor Xa and co-factors bound to activated platelets) causes a burst of thrombin production


  • A series of protease reactions causes the conversion of the soluble protein fibrinogen to insoluble fibrin strands by thrombin, leading to thrombus formation
  • Thrombin also activates Factor XIII, which stabilizes the thrombus by cross-linking fibrin
    • The resulting fibrin mesh traps and holds cellular components of the thrombus (platelets and/or red blood cells)1


  • Factor Xa plays a central role in the coagulation process that leads to haemostasis in both the original extrinsic/intrinsic model, as well as in the more recently proposed cell-based model
    • Factor Xa, with activated Factor V (Factor Va) as a co-factor, propagates coagulation by converting prothrombin (Factor II) to thrombin (Factor IIa)2
    • Factor Xa is a crucial site of amplification in the coagulation process
    • One molecule of Factor Xa catalyses the formation of approximately 1000 thrombin molecules3
  • The development of drugs that inhibit Factor Xa is, therefore, an attractive area of pharmaceutical research


  • Fibrinolysis is the process that dissolves fibrin, leading to dissolution of the thrombus
    • Plasminogen, the precursor of plasmin, breaks up fibrin in the thrombus
    • During initial thrombus formation, plasminogen activators are inhibited
    • Endothelial cells begin to secrete tissue plasminogen activators to start dissolving the thrombus as the structural integrity of the blood vessel wall is restored
  • Fibrinolysis must occur for normal blood flow to be re-established
  • Drugs that convert plasminogen to plasmin are used to treat acute, life-threatening thrombotic disorders, such as MI and ischaemic stroke4


  • Ongoing research has identified other components of the coagulation process, including microparticles and P-selectin
  • Microparticles are irregularly shaped vesicles that are smaller than platelets (<1 μm in diameter)
    • They arise from the plasma membrane of blood-borne cells during cell activation, programmed cell death, or exposure to shear stress5
  • P-selectin is a cell adhesion molecule found on the inner surface of blood vessels and on activated platelets6
  • Both microparticles and P-selectin promote thrombosis during the amplification phase of coagulation6
    • During thrombus formation, platelets accumulate at the site of vascular injury, become activated and express P-selectin6
    • P-selectin, in turn, binds to TF-bearing microparticles, allowing them to bind to activated platelets
    • TF from the microparticles then binds to and activates Factor VII


  • Thrombophilia is an inherited or acquired imbalance in the coagulation system that leads to an increased risk of thrombosis
  • Thrombophilia is typically seen in:
    • Patients with recurrent VTE or a life-threatening VTE
    • Patients aged <45 years with VTE
    • Patients with VTE and a family history of VTE
    • Patients who develop VTE with no apparent exposing risk factors
    • Women who experience multiple spontaneous abortions or stillbirths7
  • Approximately one in three patients with VTE has an inherited thrombophilia8
    • Common forms involve genetic mutations affecting Factor V (known as Factor V Leiden) and prothrombin (Factor II)
    • Rare causes include deficiencies in the natural anticoagulants protein C, protein S and antithrombin7
  • Colman RW, Clowes AW, George JN et al. Overview of hemostasis. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th edn. Colman RW, Clowes AW, George JN et al. (editors). Philadelphia: Lippincott, Williams & Wilkins; 2006. p. 1–16. Return to content
  • Hoffman M, Monroe DM. Coagulation 2006: a modern view of hemostasis. Hematol Oncol Clin North Am 2007;21:1–11. Return to content
  • Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504–1514. Return to content
  • Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914–918. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008;451:914–918. Return to content
  • Davizon P, Lopez JA. Microparticles and thrombotic disease. Curr Opin Hematol 2009;16:334–341. Return to content
  • Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008;359:938–949. Return to content
  • Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222–1231. Return to content
  • Merli GJ. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein thrombosis-pulmonary embolism in the elderly. Clin Geriatr Med 2006;22:75–92, viii-ix. Return to content

Never miss out on the latest news!

Sign up to the Thrombosis Adviser newsletter.